I agree with you 100%. You are market Guru and since you shorted this stock at $ 112.10 (before earnings) its bound to go below $ 112.10 no ifs or buts.
So far 19 million shares traded but they can not take this down under $72 ,lets see if I am right
You think those big time Wall Street investors are idiot paying $75 while stock market genius like you with crystal ball knows in and out of this stock market? LOL. I say you are getting discount here buy as much as you can.
We will see what happend
THE TERMINATION FEE ON 1.5 BILLION TO SAVE HAL.
How in the World insider are allowed to sell when company is under audit review/
Salix Pharmaceuticals (NASDAQ:SLXP) EVP William P. Forbes sold 11,079 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $95.05, for a total value of $1,053,058.95. Following the completion of the transaction, the executive vice president now directly owns 125,591 shares of the company’s stock, valued at approximately $11,937,425. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Bye Bye shorts
Lets do it today. LOL
As usual big guys know the news before us. Might close RED then slowly drift toward $70
What: Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company focused on developing and acquiring drugs targeting gastrointestinal diseases, gave its own shareholders indigestion today when the stock plunged as much as 40% on third-quarter earnings results.
So what: For the quarter, Salix Pharmaceuticals delivered $354.7 million in revenue, up 49% from the year-ago period. Adjusted net earnings per share, which excluded a hefty generally accepted accounting principles loss associated with its Santarus acquisition and the termination of its Cosmo merger, was $1.53, up 72% from the $0.89 in EPS reported a year ago. However, Wall Street had expected considerably higher revenue of $392.9 million and $1.55 in adjusted EPS.
Furthermore, Salix issued fourth-quarter guidance that includes revenue of approximately $325 million and EPS of roughly $1.16. Wall Street's consensus for the quarter was $436.9 million in sales and $1.96 in EPS. Salix wasn't even in the ballpark.
Specifically listed among its problem in the company's earnings release are high wholesaler inventory levels of nine months for Xifaxan and Apriso, seven months for Glumetza, and five months for Uceris. Salix blamed its lack of adequate distribution service arrangements for its high inventory levels and its wild revenue fluctuations on a quarter-to-quarter basis.
Finally, to add gasoline to the fire, the company's chief financial officer issued his resignation and the company during the conference call skirted around the idea of conducting an audit.
Now what: I was a fan of Salix Pharmaceuticals and felt it had the potential to motor toward $200. Sometimes you're just wrong. You take your lumps and you move on with the expectation that you can't win them all.
There's obviously still potential here, as Salix had been the object of buyout interest for years. It has amassed a pretty impressive portfolio of rapidly growing and focused products that nicely boost a larger pharmaceutical company
Don’t bet on this. CFO is leaving is not a good omen he most probably cooked the books to make the numbers and that is why independence board decided to hire OUTSIDE CONSULE to investigate before they release more information. I think more bad news is about to come out when the consul will open the closet with dirty laundry. I WILL NOT TOUCH THIS STOCK WITH 10 FEET POOL.